Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
Phase 2
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease
- Interventions
- Drug: SelK2 (Part 1)Drug: Placebo (Part 1)Drug: SelK2 (Part 2)Drug: Placebo (Part 2)
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Tetherex Pharmaceuticals Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT04540042
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd., Manchester, United Kingdom
🇬🇧Queen Anne Street Medical Centre, London, United Kingdom
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Tetherex Pharmaceuticals Corporation
- Target Recruit Count
- 207
- Registration Number
- NCT03812328
- Locations
- 🇧🇬
UMHAT Kanev AD, Ruse, Bulgaria
🇱🇻Vidzemes Hospital, Valmiera, Latvia
🇱🇹Kaunas Clinical Hospital, Kaunas, Lithuania
© Copyright 2025. All Rights Reserved by MedPath